Camlin Fine Sciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CAMLINFINE, BSE:532834 Camlin Fine Sciences Ltd.

Camlin Fine Sciences Ltd.

12 Aug 2016

147.78

-0.44%

Camlin Fine Q1FY17 Update 12Aug2016

Buy: Camlin Fine Sciences Ltd.

Phillip Capital

Key highlights: Consolidated sales (Rs 1.4bn, +14% yoy) were 4% above our estimates. EBITDA margin saw sharp correction to 11.2% (vs. estimated 21.2%) on account of – (1) production disruption in Italy subsidiary for a month period (for implementing efficient technology with target to conserve energy and reduce wastage) and initial marketing spend to launch antioxidant blends in USA. Thus, the EBITDA declined 45% yoy to Rs 157mn. The weak operating performance and higher taxes dragged PAT by 78% yoy to Rs 31mn (estimated Rs 116mn). The weak operating performance was primarily due to quarter specific execution issues at subsidiaries. The standalone financials reported 3% sales growth (to Rs 1.02bn) coupled with 160bps expansion in EBITDA margin (to 17.5%), resulting in 18% yoy growth in profits to Rs 65mn (despite higher tax incidence of 36%). Phillip Capital retain their Buy rating with an unchanged TP of Rs 135 (9x FY18 EV/EBITDA).

Camlin Fine Sciences Ltd. is trading below all available SMAs

Camlin Fine Sciences Ltd.

27 May 2016

147.78

-0.44%

Camlin Fine Q4FY16 Update 27May2016

Buy: Camlin Fine Sciences Ltd.

Phillip Capital

9 Consolidated sales were lower than our estimates, but a smart >500bps surprise in marginsledto20%higherthanexpectedearnings. 9 FY16PATperformancewas10%aheadofourestimatesduetoa150bpspositivemargin...

Camlin Fine Sciences.. has an average target of 195.00 from 1 broker.

Camlin Fine Sciences Ltd.

01 Apr 2016

147.78

-0.44%

Camlin Fine Science Initiating 1April2016

Buy: Camlin Fine Sciences Ltd.

Phillip Capital

CFIN is an established global leader of foodgrade synthetic antioxidants (market size of ~US$200mn, particularly in Tertbutylhydroquinone (TBHQ) and Butylatedhydroxyanisole (BHA). CFIN has 60% market share (capacity) with TBHQ/BHA capacity of 3600/2400tpa....